Surveys & insights

You will find here Forvis Mazars surveys and insights.

Investing in CEE: Inbound M&A report 2025/2026

Global private equity outlook 2026: Exploring new investment direction

15d20b8b1463-Web-Header.jpg.webp
The Forvis Mazars global private equity outlook 2026 delivers exclusive insights from over 800 private equity professionals across regions, sectors and investment strategies. Explore our global report and insights into how investor priorities are evolving amid changing market conditions.

Read more

Forvis Mazars CEE deal advisory highlights 2025

ed30dcc1c750-HU-deal-adv-highlights.jpg.webp
Our deal advisory highlights feature a selection of projects that we advised on throughout the region in 2025.

Read more

New Forvis Mazars research identifies compliance, accuracy and visibility to reshape payroll performance across Europe

e38042adc472-poza-1.jpg.webp
Based on the views of more than 1,000 payroll, HR and finance leaders from 13 markets, the 'Compliance, accuracy, and visibility: the 3 non-negotiables in modern European payroll' report reveals how payroll has evolved from a transactional necessity into a strategic pillar of organisational trust, data governance and people experience.

Read more

CEE banking outlook 2025

a8e038b042df-2.jpg.webp
Our new study, the CEE Strategic resilience in banking: outlook 2025, combines independent market intelligence with practical insights from financial services professionals advising banks across the region. The report examines trends in profitability, capital adequacy, regulatory evolution, digitalisation, securitisation and ESG integration across six CEE markets.

Read more

CEE insurance outlook 2025

fb2e1e534743-GettyImages-1149993021.jpg.webp
Our new "CEE strategic resilience in insurance: outlook 2025" reveals that the region’s insurers have expanded non-life premiums from €18 billion in 2018 to €28.5 billion in 2024, a 58% surge that outpaces many mature Western markets.

Read more

Report: Re-shoring life sciences for a sustainable future

96ee1681089a-Pharma-study-1600x500.jpg.webp
The pandemic, geopolitical tensions and the climate emergency have revealed the vulnerabilities of Europe’s life sciences industry. Relocating pharmaceutical and medtech production is no longer a choice but a strategic necessity to safeguard sovereignty, strengthen competitiveness and ensure long-term sustainability.

Read more

C-suite barometer: life sciences and pharmaceuticals sector view

9a08ad17008b-Web-banner-C-suiteLS.jpg.webp
In a year marked by global uncertainty, shifting regulations and fast-moving innovation, leaders in the life sciences and pharmaceuticals sector are redefining their strategic priorities. Drawing on insights from executives from across more than 35 countries, our latest report captures how sector players are navigating complexity, investing in growth and positioning themselves for long-term success in a competitive landscape.

Read more

Financial reporting of EU banks benchmark study 2025: CEE Supplement

727e6254cf33-Webpage-image.jpg.webp
In parallel with the ninth edition of Forvis Mazars benchmark study on the financial reporting of European banks, Forvis Mazars in Poland prepared a dedicated supplement focusing on Central and Eastern Europe (CEE).

Read more

Financial reporting of European banks: benchmark study 2025

7a2dcf5696da-GettyImages-1728002245.jpg.webp
As European banks move into 2025 amid renewed U.S. tariffs and heightened geopolitical tensions, is this calm before the storm? Throughout 2024, we observed a continued reduction in credit risk buffers, despite persistent macroeconomic pressures and geopolitical challenges. As we examine the year-end results of the region’s largest institutions, what do the figures reveal about how they manage expected credit losses (ECLs) in an increasingly unpredictable environment?

Read more